Literature DB >> 31356922

Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.

Zinah Zamil Al-Ghezi1, Philip Brandon Busbee1, Hasan Alghetaa1, Prakash S Nagarkatti2, Mitzi Nagarkatti1.   

Abstract

Currently, a combination of marijuana cannabinoids including delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is used as a drug to treat muscle spasticity in patients with Multiple Sclerosis (MS). Because these cannabinoids can also suppress inflammation, it is unclear whether such patients benefit from suppression of neuroinflammation and if so, what is the mechanism through which cannabinoids act. In the currently study, we used a murine model of MS, experimental autoimmune encephalomyelitis (EAE), to study the role of gut microbiota in the attenuation of clinical signs of paralysis and inflammation caused by cannabinoids. THC + CBD treatment attenuated EAE and caused significant decrease in inflammatory cytokines such as IL-17 and IFN-γ while promoting the induction of anti-inflammatory cytokines such as IL-10 and TGF-β. Use of 16S rRNA sequencing on bacterial DNA extracted from the gut revealed that EAE mice showed high abundance of mucin degrading bacterial species, such as Akkermansia muciniphila (A. muc), which was significantly reduced after THC + CBD treatment. Fecal Material Transfer (FMT) experiments confirmed that THC + CBD-mediated changes in the microbiome play a critical role in attenuating EAE. In silico computational metabolomics revealed that LPS biosynthesis, a key component in gram-negative bacteria such as A. muc, was found to be elevated in EAE mice which was confirmed by demonstrating higher levels of LPS in the brain, while treatment with THC + CBD reversed this trend. EAE mice treated with THC + CBD also had significantly higher levels of short chain fatty acids such as butyric, isovaleric, and valeric acids compared to naïve or disease controls. Collectively, our data suggest that cannabinoids may attenuate EAE and suppress neuroinflammation by preventing microbial dysbiosis seen during EAE and promoting healthy gut microbiota.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akkermansia muciniphila; CBD; EAE; Gut microbiome; LPS; Multiple sclerosis; SCFAs; THC

Year:  2019        PMID: 31356922      PMCID: PMC6866665          DOI: 10.1016/j.bbi.2019.07.028

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  67 in total

Review 1.  Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS).

Authors:  Simon Glatigny; Estelle Bettelli
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

Review 2.  Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis.

Authors:  Nina L Cluny; Raylene A Reimer; Keith A Sharkey
Journal:  Brain Behav Immun       Date:  2012-01-17       Impact factor: 7.217

3.  Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis.

Authors:  Qin Zeng; Xiyuan Liu; Chen Chen; Xiaobo Sun; Huijuan Li; Yifan Zhou; ChunPing Cui; Yuge Wang; Yu Yang; Aimin Wu; Yaqing Shu; Xueqiang Hu; Zhengqi Lu; Song Guo Zheng; Wei Qiu; Yongjun Lu
Journal:  Neurochem Int       Date:  2019-05-17       Impact factor: 3.921

4.  CD44 deletion leading to attenuation of experimental autoimmune encephalomyelitis results from alterations in gut microbiome in mice.

Authors:  Kumaraswamy Naidu Chitrala; Hongbing Guan; Narendra P Singh; Brandon Busbee; Alexa Gandy; Pegah Mehrpouya-Bahrami; Mitra S Ganewatta; Chuanbing Tang; Saurabh Chatterjee; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Eur J Immunol       Date:  2017-06-06       Impact factor: 5.532

5.  Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

Authors:  H M Meinck; P W Schönle; B Conrad
Journal:  J Neurol       Date:  1989-02       Impact factor: 4.849

Review 6.  Cannabinoids and experimental models of multiple sclerosis.

Authors:  Ilona Kubajewska; Cris S Constantinescu
Journal:  Immunobiology       Date:  2009-09-17       Impact factor: 3.144

Review 7.  Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.

Authors:  M S Freedman
Journal:  Eur J Neurol       Date:  2013-11-15       Impact factor: 6.089

8.  QIIME allows analysis of high-throughput community sequencing data.

Authors:  J Gregory Caporaso; Justin Kuczynski; Jesse Stombaugh; Kyle Bittinger; Frederic D Bushman; Elizabeth K Costello; Noah Fierer; Antonio Gonzalez Peña; Julia K Goodrich; Jeffrey I Gordon; Gavin A Huttley; Scott T Kelley; Dan Knights; Jeremy E Koenig; Ruth E Ley; Catherine A Lozupone; Daniel McDonald; Brian D Muegge; Meg Pirrung; Jens Reeder; Joel R Sevinsky; Peter J Turnbaugh; William A Walters; Jeremy Widmann; Tanya Yatsunenko; Jesse Zaneveld; Rob Knight
Journal:  Nat Methods       Date:  2010-04-11       Impact factor: 28.547

Review 9.  A simple practice guide for dose conversion between animals and human.

Authors:  Anroop B Nair; Shery Jacob
Journal:  J Basic Clin Pharm       Date:  2016-03

10.  Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol.

Authors:  Nina L Cluny; Catherine M Keenan; Raylene A Reimer; Bernard Le Foll; Keith A Sharkey
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more
  26 in total

1.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 2.  Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.

Authors:  Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-27       Impact factor: 73.082

Review 3.  Targeting the gut to treat multiple sclerosis.

Authors:  Laura Ghezzi; Claudia Cantoni; Gabriela V Pinget; Yanjiao Zhou; Laura Piccio
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

4.  The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies.

Authors:  Frances R Henshaw; Lauren S Dewsbury; Chai K Lim; Genevieve Z Steiner
Journal:  Cannabis Cannabinoid Res       Date:  2021-04-28

5.  Administration of Δ9-Tetrahydrocannabinol (THC) Post-Staphylococcal Enterotoxin B Exposure Protects Mice From Acute Respiratory Distress Syndrome and Toxicity.

Authors:  Amira Mohammed; Hasan Alghetaa; Muthanna Sultan; Narendra P Singh; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

Review 6.  Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome.

Authors:  Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  Nutrients       Date:  2019-08-20       Impact factor: 5.717

Review 7.  The role of the gut microbiome in opioid use.

Authors:  Michelle Ren; Shahrdad Lotfipour
Journal:  Behav Pharmacol       Date:  2020-04       Impact factor: 2.293

Review 8.  Cannabidiol and Neurodevelopmental Disorders in Children.

Authors:  Keith A Kwan Cheung; Murray D Mitchell; Helen S Heussler
Journal:  Front Psychiatry       Date:  2021-05-21       Impact factor: 4.157

Review 9.  Nutritional and ecological perspectives of the interrelationships between diet and the gut microbiome in multiple sclerosis: Insights from marmosets.

Authors:  Maria Elisa Perez-Muñoz; Scott Sugden; Hermie J M Harmsen; Bert A 't Hart; Jon D Laman; Jens Walter
Journal:  iScience       Date:  2021-06-10

Review 10.  Gut-Brain Axis and Neurodegeneration: State-of-the-Art of Meta-Omics Sciences for Microbiota Characterization.

Authors:  Bruno Tilocca; Luisa Pieroni; Alessio Soggiu; Domenico Britti; Luigi Bonizzi; Paola Roncada; Viviana Greco
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.